Healthy Returns Summit: Investing in health care innovation
THE PATH FORWARD FOR THE HEALTH CARE INDUSTRY AT A TIME OF UNPRECEDENTED CHALLENGES
CNBC presents a virtual event featuring top health care CEOs, technologists and investors, exploring the ways the most innovative companies are addressing the coronavirus crisis, and the lasting effects the crisis will have on the industry.
From vaccines and treatments, to new tech and processes, to modeling the financial impacts and effects on legacy and upstart health care companies, Healthy Returns will feature some of the most influential voices in health care.
Led by CNBC’s anchors and reporters, Healthy Returns will hone in on the groundbreaking ideas that will help mitigate the global pandemic, and will transform the health care industry for years to come.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.
Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.
Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.
Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.
In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.
John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.
He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.
Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.
Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.
In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.
In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.
Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.
Sharmin Ghaznavi, MD, PhD, is the Associate Director and the Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital. Dr. Ghaznavi also serves as a psychiatrist at the MGH Dauten Family Center for Bipolar Treatment Innovation and is an instructor in Psychiatry at Harvard Medical School. Her research interests are the neural correlates of cognitive processes underlying mental illness. Dr. Ghaznavi has been the recipient of the Dupont-Warren and Livingston psychiatric research fellowships from Harvard Medical School and a 2012 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation.
Dr. Ghaznavi received her undergraduate degrees in biology, brain and cognitive sciences, and philosophy from the Massachusetts Institute of Technology. She obtained her medical degree and PhD in neuroscience from Yale University and completed a residency in adult psychiatry at the Mass General/McLean Psychiatry Residency Program. As a resident, Dr. Ghaznavi received the Thomas P. Hackett award for academic and research excellence and the Joyce Tedlow Award from the mood and anxiety disorders board for efforts to integrate psychotherapy, psychopharmacology and research.
Dr. Fahrenkopf is responsible for the strategy, operations, and management of HSS Health, a digital health initiative at HSS. An executive specializing in value-based care, population health, and strategy, Dr. Fahrenkopf has held leadership positions across the healthcare industry, including Highmark Blue Cross Blue Shield, Castlight Health, and Socially Determined. In addition, she served as the Deputy Under Secretary for Health for Community Care at the Veterans Health Administration and was an Associate Principal at McKinsey & Company in their healthcare practice. A pediatrician by training, Dr. Fahrenkopf served on the medical staff at Boston Children’s Hospital and was on faculty at Harvard Medical School. Dr. Fahrenkopf earned her MD from Yale School of Medicine and her MPH from Harvard School of Public Health.
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. He serves on a variety of professional advisory boards and gives numerous invited speeches for pharmaceutical and technology firms, health insurance plans, hospitals, physician organizations, universities, and public agencies. At Berkeley, Professor Robinson’s research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and over 140 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. He teaches classes on public policy, health insurance, and the economics of the life sciences industry. In his personal life, Professor Robinson is married, has four children, participates actively in open water swimming, speaks five languages, and holds dual citizenship with the United States and France.
Catherine MacLean, MD, PhD, is the Chief Value Medical Officer at HSS where she leads the development and execution of strategies to measure, report on and improve health care value. She directs the HSS Center for the Advancement of Value in Musculoskeletal Care, which pulls together expertise from HSS and collaborating organizations to rapidly develop and deploy programs, systems and tools that will fast-track the delivery of high-value musculoskeletal care at HSS and beyond. She is a nationally recognized expert on healthcare quality and value with diverse leadership experience including strategic planning, implementation and evaluation of population health, quality and value programs. Dr. MacLean obtained her MD from Washington University, St. Louis. She completed training in internal medicine at the Harbor-UCLA Medical Center, and in rheumatology at UCLA’s Center for the Health Sciences. She obtained her PhD in health services from UCLA’s School pf Public Health.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Previously, he served as CEO and Chairman of Foundation Medicine (NASDAQ:FMI), a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient (NASDAQ:CLRT), a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Thrive Earlier Detection, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Providence/St. Joseph Health).
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
Jim Cramer believes there is always a bull market somewhere, and he wants to help you find it. He is host of CNBC's "Mad Money," (M-F, 6PM ET) featuring lively guest interviews, viewer calls and most important, the unmatched, fiery opinions of Cramer himself. He serves as the viewer's personal guide through the confusing jungle of Wall Street investing—navigating through both opportunities and pitfalls with one goal in mind—to help them make money.
Cramer is also co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street" (M-F, 9AM-11AM ET) and the founder of TheStreet, a multimedia provider of financial commentary.
He graduated from Harvard College where he was president and editor-in-chief of the prestigious daily, The Harvard Crimson. After graduation, he became a reporter for the Tallahassee Democrat and later for the Los Angeles Herald Examiner, where he covered stories ranging from homicides to sporting events.
Cramer is a former hedge fund manager and founder/owner and senior partner of Cramer Berkowitz. His compounded rate of return was 24 percent after all fees for 14 years at Cramer Berkowitz. He retired from his hedge fund in 2001, where he finished with one of the best records in the business, including having 36 percent-plus year in 2000.
He helped Steve Brill launch American Lawyer magazine before attending Harvard Law School and earning a law degree. Upon graduating and passing the New York State Bar Examination and being admitted to the N.Y. State Bar, Cramer joined Goldman Sachs in sales and trading. While at Goldman, Cramer wrote for The New Republic about stock market issues.
In December 2013, he published the book, "Jim Cramer's Get Rich Carefully," in which he creates a guide to high-yield, low-risk investing. Cramer is also the author of "Jim Cramer's Getting Back to Even," "Stay Mad for Life: Get Rich, Stay Rich," "Mad Money: Watch TV, Get Rich," "Jim Cramer's RealMoney" and "Confessions of a Street Addict."
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Subject to change
Coronavirus: Where We Are, Where We’re Going
Since the coronavirus hit the U.S. in January, it has had a profound effect on our society. We look at the latest on the trajectory of the pandemic, the search for a vaccine and effective treatments and what our “new normal” will look like in the months ahead. Scott Gottlieb, Fmr. Commissioner, FDA Meg Tirrell, Senior Health and Science Reporter, CNBC Interviewer: Tyler Mathisen, Co-anchor, “Power Lunch”; Vice President, Events Strategy, CNBC Watch the full interview
Big Pharma’s Big Moment
The pharmaceutical industry has been a favorite target for politicians, payers and patients. Will the industry’s collaborative efforts to combat the coronavirus crisis change public perception? We’ll discuss this issue as well as look as examine a top CEO’s vision for his company’s future as he manages through today’s crisis. Giovanni Caforio, Chairman and CEO, Bristol Myers Squibb
Interviewer: Jim Cramer, Host of “Mad Money” and Co-Anchor CNBC’s “Squawk on the Street,” CNBC Watch the full interview
Need to Know: Seeking More and Better Testing
The U.S. response to the coronavirus pandemic has been hampered by a severe shortage of tests. To overcome this crisis and return to normalcy, more, better and new tests for COVID-19 antibodies will be necessary. How can the public and private sectors work together to achieve this goal, and how can the results be leveraged for a better understanding of how the virus works? Jessica Mega, Co-Founder and Chief Medical and Scientific Officer, Verily Tom Polen, CEO, BD (Becton, Dickinson and Company)
Interviewer: Chrissy Farr, Health and Technology Reporter, CNBC.com Watch the full interview
New Models for Drug Development
It is said that necessity is the mother of invention. As pharmaceutical companies are using new technologies and processes to address the global pandemic, and regulatory agencies are fast-tracking approvals and trials, are we moving into a new era of drug development? Stéphane Bancel, CEO, Moderna Leonard Schleifer, Founder and CEO, Regeneron
Interviewer: Meg Tirrell, Senior Health and Science Reporter, CNBC Watch the full interview
Frenemies: New Collaboration Models
Once-fierce competitors are now collaborating on vaccine discovery, while also working to keep their exclusive pipelines primed. Is this a model that will outlast the crisis? We’ll take a deep dive into pharma R&D, for coronavirus and beyond. Hal Barron, Chief Scientific Officer and President, R&D, GSK John Reed, Executive Vice President, Global Head of R&D, Sanofi
Interviewer: Meg Tirrell, Senior Health and Science Reporter, CNBC Watch the full interview
What’s Next for Biotech and Health-Care Start-ups?
Once-promising venture-backed start-ups are folding, while some companies with possible treatments have enjoyed a moment in the sun. But where will values be once the crisis is over? Which companies are set to gain — or lose — the most? Mike Pellini, Managing Partner, Section 32 Julie Sunderland, Co-founder and Managing Partner, Biomatics Capital
Interviewer: Chrissy Farr, Health and Technology Reporter, CNBC.com Watch the full interview
Data Is the New Rx
Whether it is tracking the coronavirus outbreak or finding candidates for clinical trials, pinpointing marketing efforts or making health care more cost efficient, data is transforming the industry. We’ll examine the ways that transformation is happening now and how it will accelerate in the future. Arif Nathoo, Co-Founder and CEO, Komodo Health
Peter Lee, Corporate Vice President, Microsoft Research & Incubation
Interviewer: Bertha Coombs, Reporter, CNBC Watch the full interview
High Value Care Post-COVID | Sponsored & Programmed by HSS
Hospitals and health systems have undergone rapid changes to meet the needs of COVID-19 patients. This session explores how care can be delivered to keep patients safe and how the US will pay for it. Amy Fahrenkopf, MD, MPH, SVP and General Manager, HSS Health, Hospital for SpecialSurgery James Robinson, PhD, MPH, Leonard D. Schaeffer Professor of Health Economics Director, Berkeley Center for Health Technology University of California
Interviewer: Catherine MacLean, MD, PhD, Chief Value Medical Officer, Hospital for Special Surgery Watch the full interview
General Session Rejoins
Epic: A Unique View of the Crisis
With their software being used in thousands of medical offices, clinics and hospitals, Epic has a unique window into the coronavirus crisis. In a rare interview, we will talk with the company’s legendary founder and CEO. Judy Faulkner, Founder and CEO, Epic
Interviewer: Bertha Coombs, Reporter, CNBC Watch the full interview
Innovation at Scale
Since stepping in as CEO just over a year ago, Albert Bourla has already been named America’s top pharmaceutical CEO by Institutional Investor. In a rare interview, we’ll talk to him about his company’s multipronged fight against Covid-19 and Pfizer’s future. Albert Bourla, Chairman and CEO, Pfizer
Interviewer: Meg Tirrell, Senior Health and Science Reporter, CNBC Watch the full interview
Lessons Learned and the Path Forward
The coronavirus has exposed big cracks in the U.S. health system. How can health-care leaders use the crisis as a catalyst for change? Julie Gerberding, Chief Patient Officer, Merck; Fmr. Director, Centers for Disease Control and Prevention (CDC) Eric Topol, Executive Vice President, Scripps Research; Founder and Director, Scripps Research Translational Institute; Bestselling Author
Interviewer: Tyler Mathisen, Co-anchor, “Power Lunch”; Vice President, Events Strategy, CNBC Watch the full interview
LEARN MORE & SUBSCRIBE
Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.
You can also visit cnbc.com/healthy-returns for relevant content from the event and all-things health care investing and innovation.
HSS is the world’s leading academic medical center dedicated to musculoskeletal health, powered by Hospital for Special Surgery – ranked #1 in the nation for Orthopedics for the past eleven years in a row by U.S. News & World Report. HSS helps some of the nation’s largest and highest-performing corporations with population-scale support to improve workforce wellness and performance.
Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.
Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.
In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.
Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.
Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.
Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.
Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.
Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since December 2017.
He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, served a number of biotechnology companies on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as a member of the Casebia Board of Directors.
He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.
Dr. Jennifer Schneider is the President of Livongo. In this role, she is responsible for product, data science, engineering, marketing, and clinical operations. Dr. Schneider previously served as the company’s Chief Medical Officer where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches.
Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health, most recently as Chief Medical Officer. She also has held leadership roles in the provider setting as a health outcomes researcher and Chief Resident at Stanford University, and has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross, a Doctor of Medicine degree from Johns Hopkins School of Medicine, and a Master of Science degree in Health Services Research from Stanford University. She completed her internal medicine residency at Stanford University Hospital.
Dr. Schneider is a frequent speaker about innovation in healthcare, where she shares her unique perspective as a practicing physician, health services researcher, senior executive and individual who has lived with Type 1 diabetes for more than 30 years. She has three children and is an avid runner and athlete, having completed her first IronMan in 2016.
David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years. He is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements and partnering with physicians to focus on wellness, and improving clinical quality. With operations and capabilities in more than thirty countries, Cordani leads Cigna’s approximately 43,000 employees in improving the health, well-being and sense of security of more than 95 million customer relationships.
Cordani joined Cigna in 1991; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.
Prior to joining Cigna, Cordani was with Coopers & Lybrand. He actively works with the Achilles International Freedom Team of Wounded Veterans and ChildObesity180, where he is a charter board member. He also supports organizations including March of Dimes and The Juvenile Diabetes Research Foundation. In addition, he is founder of The David and Sherry Cordani Family Foundation, reflecting the Cordani family’s deep commitment to supporting community health and well-being. Cordani was named to the General Mills Board of Directors in 2014 and to the U.S.-India Business Council Board of Directors in 2015.
David Cordani is an accomplished triathlete, having competed in more than 125 triathlons. He earned a bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.
Jorge Conde is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and health.
Prior to joining a16z, Jorge served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Jorge also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.
Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University.
Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a 2015 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He serves on the board of the Museum of Science, Boston.
Dr. Harrison is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is leading Intermountain to embrace bold new approaches focused on improving health while continuing to make healthcare more effective, accessible, and affordable. As a result, Intermountain’s 37,000 employees—who are all called caregivers—continue to re-define value-based care and serve people in new ways.
Dr. Harrison is a national and international thought leader on healthcare transformation and innovation. In 2018, he ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders. He also tied for second on Modern Healthcare’s list of the 100 Most Influential People in Healthcare.
Two examples of innovations Intermountain is leading:
• Intermountain launched Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation.
• Intermountain is a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration between numerous community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital, such as chronic hunger, affordable housing, joblessness, personal safety, etc.
Dr. Harrison’s previous healthcare leadership experience has included service as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer at Cleveland Clinic.
He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a residency at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University.
Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.
Susan DeVore is CEO of Premier with approximately 30 years of experience. DeVore’s tenure with Premier has centered on driving innovation in healthcare and leading the industry through profound change by engaging stakeholders to co-develop solutions that support high-quality, efficient and sustainable care delivery models.
DeVore is an industry-leading thinker who has consistently been named multiple times to Modern Healthcare's 100 Most Influential People and Top 25 Women in Healthcare lists. She recently received the Charlotte Business Journal’s 2018 Women in Business Lifetime Achievement Award, was named to Becker’s Hospital Review’s 2017 100 Great Healthcare Leaders to Know and was recognized as a 2016 UNC Charlotte Distinguished Alumnus.
DeVore currently serves on the Board of Trustees for the Healthcare Leadership Council; is Board Member of the Coalition to Protect America’s Healthcare; is a Board Member, Finance Committee Member and Audit Committee Chair of the Medicare Rights Center; is a Member of the Charlotte Chamber Executive Committee; is a Member of the Charlotte Executive Leadership Council; and a Member of the UNC Charlotte Board of Trustees. She also serves as a Member of the National Academy of Medicine and the Aspen Health Strategy Group, and most recently joined the Board of Unum Group, a NYSE-listed company, as a Director and Audit Committee Member.
Under DeVore's leadership, Premier has been named as one of the World's Most Ethical Companies for past 11 years, received the Malcolm Baldrige National Quality Award and earned the Best in KLAS title for Overall Healthcare Management Consulting.
DeVore obtained a bachelor’s degree from the University of North Carolina at Charlotte and a Master of Management degree from McGill University.
Tim Wentworth leads Express Scripts and Cigna Services. In this role, Wentworth oversees the Express Scripts business as well as independent services, including eviCore.
Wentworth formerly served as President and Chief Executive Officer of Express Scripts, where he was responsible for all aspects of the company’s strategic direction and core business. He joined Express Scripts when the company merged with Medco in April 2012. At Medco, he led the employer and key accounts organizations for nearly 14 years. He also served as President and CEO of Accredo, the company's specialty pharmacy.
Wentworth earned a bachelor's degree in industrial and labor relations from Cornell University and an associate's degree in business from Monroe Community College.
As Collective Health’s Co-Founder and Chief Health Officer, Dr. Rajaie Batniji oversees partnerships with healthcare networks and providers, analytics and research, and Collective Health’s employee health management programs. Collective Health brings together Dr. Batniji’s academic and professional careers as both a physician and as a political economist, and his aspiration to create a better and more efficient health insurance experience.
Dr. Batniji is also a Clinical Assistant Professor of Medicine at the Stanford University School of Medicine, where he previously trained in Internal Medicine. He received a DPhil in International Relations (Political Economy) from Oxford University, where he was a Marshall Scholar, an MD from UCSF, and BA and MA degrees from Stanford University.
Paul Dabrowski is CEO of Synthego. He founded the company with his brother, Michael Dabrowski, and together they developed the company’s world-class commercial offering for genome engineering. Before Synthego, Paul was the lead digital designer for the Falcon 9 rocket and Dragon spacecraft at SpaceX. He also founded a mobile software company and designed a portable electron microscope for DNA sequencing. Paul was born in Illinois to Polish immigrants and earned his MS/BS in Computer Engineering from the University of Illinois at Urbana-Champaign.
Ed Ellison, MD, serves as Executive Medical Director/Chairman of the Board, Southern California Permanente Medical Group (SCPMG); Chairman of the Board and CEO, The Southeast Permanente Medical Group. He also is Co-CEO of The Permanente Federation, LLC, a consortium of all the Permanente Medical Groups in the nation, supporting the work of more than 22,000 Kaiser Permanente physicians in the eight Kaiser Permanente regions across the country.Dr. Ellison joined SCPMG in 1984 as a family medicine physician and has served in multiple roles with the organization. In 2002, Dr. Ellison was appointed area medical director for Orange County and joined SCPMG’s Board of Directors. He is a past recipient of Orange County’s Family Medicine Physician of the Year. After completing his undergraduate degree at Duke University, Dr. Ellison received his medical degree from the University of Virginia. He completed his residency training in Family Medicine at Halifax Hospital Medical Center, University of South Florida, where he served as chief resident. Dr. Ellison is board certified in Family Medicine and is a diplomate of the American Academy of Family Physicians. He has attended the Advanced Leadership Program at the University of North Carolina at Chapel Hill and Harvard’s Advanced Management Program.